

Remarks

Rejection Under 35 U.S.C. § 102(a)

Claims 1-4, 8-10, 16-18, and 21 stand rejected as anticipated by Ono (*J. Neurochem.*, 2003). To advance prosecution, claims 1-4, 8-10, 16, 18, and 21 are canceled, and claim 17 is amended to delete “myricetin,” which distinguishes the claimed subject matter from the disclosure of Ono.

Rejection Under 35 U.S.C. § 103(a)

Claims 5-7 and 11-13 stand rejected as obvious over Ono in view of Somerville (*J. Gen. Virol.*, 1989). Claims 5-7 and 11-13 are canceled, which moots this rejection.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Date: August 12, 2009

By: /Lisa M. Hemmendinger/

Lisa M. Hemmendinger
Registration No. 42,653

Customer No. 22907
202-824-3000